PHILADELPHIA, July 10, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, today announced the appointment of A. William (Bill) Newbould to the newly created position of Vice President, Investor Relations. Reporting directly to Eurand's Chief Executive Officer Gearoid Faherty, Newbould will be responsible for developing and implementing the Company's investor relations program. He will be based in Eurand's Yardley, Pennsylvania, office.
"I am delighted to welcome Bill Newbould to the Eurand team," Faherty said. "Having served more than 20 years as an investor relations executive, including the last 11 in positions of increasing responsibility in the specialty pharmaceutical and biotech industries, he brings an extensive network of contacts and a wealth of experience to an area that is becoming an increasingly important component of Eurand's growth."
Previously, Newbould was Vice President, Corporate Communications, at Endo Pharmaceuticals Inc., a specialty pharmaceuticals company where he was responsible for investor and media relations, product communications and public relations. Prior to joining Endo, he was Director, Corporate Communications, for Centocor, Inc., a Johnson & Johnson subsidiary, which he joined in 1997 as Manager, Investor Relations. His career also includes investor relations experience in the water utility and financial services industries.
Newbould received a bachelor's degree from Gettysburg College and completed course work at Fairfield University's Graduate School of Corporate and Political Communication. He is a member of the National Investor Relations Institute (NIRI) and the Greater Philadelphia Senior Executives Group.
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four partnered products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand completed two phase III clinical trials for EUR-1008 (Zentase), intended for the treatment of Exocrine Pancreatic Insufficiency and, as announced on June 18, 2008, received an approvable letter from the FDA for its NDA for this product. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-masking/fast-dissolving formulations and drug conjugation.
Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand's website at www.eurand.com.
This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to the future and status of our NDA filing for EUR-1008, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "potentially", "anticipates", "could", "calls for" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA does not approve our NDA or continues to delay approval; the outcome of any discussions with the FDA; and unexpected delays or additional requirements in preparation of materials for submission to the FDA as a part of our NDA filing. Forward-looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements.